Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 7Carcinoma, Ovarian Epithelial 4Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasm Epithelial 1Osteosarcoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

olaparib 1liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasm Epithelial × Bortezomib × Gynecologic × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡